Please login to the form below
sotagliflozin
This page shows the latest sotagliflozin news and features for those working in and with pharma, biotech and healthcare.
FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes
It also turned down Lexicon Pharma and Sanofi’s SGLT2 inhibitor Zynquista (sotagliflozin) for this use in December, once again despite an earlier approval in Europe.
Latest news
-
FDA advisors say no to empagliflozin in type 1 diabetes
Earlier this year the panel was split on whether they should back approval of Lexicon Pharma’s Zynquista (sotagliflozin) as an insulin adjunct in these patients, and the FDA’s subsequent
-
Sanofi reveals positive phase 3 results for long-acting insulin Toujeo
The drug, Zynquista (sotagliflozin), was a key element in Sanofi’s plans to rebuild its diabetes franchise following the loss of patent protection for its basal insulin Lantus.
-
Sanofi exits Zynquista alliance with Lexicon
Zynquista (sotagliflozin).
-
Success for AZ, setback for Sanofi in type 1 diabetes
Sanofi has been less fortunate with its US marketing application for Lexicon Pharma-partnered dual SGLT1/SGLT2 inhibitor Zynquista (sotagliflozin) alongside insulin in type 1 diabetes, however, as this was rejected
-
CHMP backs Lynparza in breast cancer, Dupixent in asthma
There was also another positive opinion for Sanofi, this time for its Lexicon Pharma-partnered SGLT1/2 inhibitor Zynquista (sotagliflozin) as an oral add-on to insulin therapy to improve blood
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2015
Staying with diabetes, so strategically important, Sanofi put in place a collaboration with Lexicon Pharmaceuticals for sotagliflozin (LX4211), an oral treatment for type 1 and type 2 diabetes. ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Manager
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Senior Medical Writer
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
-
Publications Director
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- bluebird bio aiming to separate business units by year-end
- InSite Events™ selected as an honorable mention in Fast Company’s 2021 World Changing Ideas Awards
- THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide
- Moderna’s booster vaccines increase neutralising antibodies against COVID-19 variants
- FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
- US backs proposal to waive IP protection for COVID-19 vaccines
- Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Why female mentorship is so powerful in pharma
- CanSinoBIO considers booster jab for COVID-19 vaccine
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Moderna COVID-19 vaccine shortfall could affect UK supply
- NICE sets out plans for ‘ambitious’ five-year strategy
- Working in true partnership in a time of change
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
- COVID-proof: How Teams are Creating Launch Intensity thru Adversity
- Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
